The following is a summary of “Iron carboxymaltose in the management of iron deficiency anemia in pregnancy: a subgroup analysis of a multicenter real-world study involving 1191 pregnant women,” published in the November 2022 issue. medicine by Trivedi et al.
Clinical data supporting the efficacy and safety of iron carboxymaltose (FCM) infusion in pregnant Indian women with iron deficiency anemia (IDA) were lacking. In a real-world setting, researchers sought to evaluate the efficacy and safety of intravenous (IV) FCM in Indian pregnant women on IDA at 4 weeks for the study.
This was a retrospective, multicenter, real-world subgroup analysis of the PROMISE trial. At 4 ± 1 weeks, data on demographic and hematologic characteristics, patient adverse event reports, and physician clinical assessments of efficacy and safety were also analyzed.
In 1,191 pregnant women included in the subgroup study, IV FCM significantly increased hemoglobin (Hb) by 2.8 g/dL and serum ferritin by 30.03. metersg/L for 4 weeks (P.both < 0.001). Hb increased by 3.6 g/dL (P.< 0.001) and serum ferritin up to 16.96 metersg/L (P. = 0.12), with a statistically significant increase in 103 pregnant women with severe IDA. A significant increase of 33 μg/L in serum ferritin and 2.74 g/dL in Hb (P.< 0.001) was found in 978 pregnant women with mild IDA. Mean cell volume, mean cell hemoglobin, hematocrit, and red blood cell count all increased significantly (P.< 0.001 for all). Pregnant women (n = 26) with moderate her IDA had a significantly elevated Hb of 1.99 g/dL (P.< 0.001). Her 8.6% of pregnant women reported side effects. There were no brand new warning signs of safety or alarming side effects.According to the physician's global assessment, 99.2% of pregnant women who received IV FCM and 98.6% of them had very good efficacy and safety, respectively. was good for
In the second and third trimesters of pregnancy, at all levels of IDA, IV FCM effectively treated anemia in just 4 weeks with excellent safety. The use of FCM in routine clinical practice was supported by physicians’ overall positive assessment of the efficacy and safety of FCM in pregnant women at IDA.